Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D1VB
|
||||
| Former ID |
DNC013492
|
||||
| Drug Name |
Tyr-Pro-Phe-D-2-Nal-NH2
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C36H39N5O5
|
||||
| Canonical SMILES |
C1CC(N(C1)C(=O)C(CC2=CC=C(C=C2)O)N)C(=O)NC(CC3=CC=CC=C3<br />)C(=O)NC(CC4=CC5=CC=CC=C5C=C4)C(=O)N
|
||||
| InChI |
1S/C36H39N5O5/c37-29(20-24-13-16-28(42)17-14-24)36(46)41-18-6-11-32(41)35(45)40-31(21-23-7-2-1-3-8-23)34(44)39-30(33(38)43)22-25-12-15-26-9-4-5-10-27(26)19-25/h1-5,7-10,12-17,19,29-32,42H,6,11,18,20-22,37H2,(H2,38,43)(H,39,44)(H,40,45)/t29-,30+,31-,32-/m0/s1
|
||||
| InChIKey |
UHSIKTZSFPWTDC-RACKDBBVSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Mu-type opioid receptor | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Enkephalin release | |||||
| Pathway Interaction Database | IL4-mediated signaling events | ||||
| Reactome | Peptide ligand-binding receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| Opioid Signalling | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3. Epub 2008 Jan 8.Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.